Abstract: This invention provides an isolated nucleic acid molecule encoding a mammalian rB21a transporter, an isolated protein which is a mammalian rB21a transporter, vectors comprising an isolated nucleic acid molecule encoding a mammalian rB21a transporter, mammalian cells comprising such vectors, antibodies directed to the mammalian rB21a transporter, nucleic acid probes useful for detecting a nucleic acid molecule encoding mammalian rB21a transporter, antisense oligonucleotides complementary to any unique sequences of a nucleic acid molecule which encodes a mammalian rB21a transporter, pharmaceutical compounds related to mammalian rB21a transporter, and nonhuman transgenic animals which express DNA encoding a normal or a mutant mammalian rB21a transporter. This invention further provides methods for determining substrate binding, detecting expression, drug screening, and treatments for alleviating abnormalities associated with the mammalian rB21a transporter.

Abstract: This invention provides an isolated nucleic acid molecule encoding a human .alpha..sub.1a adrenergic receptor, an isolated nucleic acid molecule encoding a human .alpha..sub.1b adrenergic receptor and an isolated nucleic acid molecule encoding a human .alpha..sub.1c adrenergic receptor, an isolated protein which is a human .alpha..sub.1a adrenergic receptor, an isolated protein which is .alpha..sub.1b adrenergic receptor and a isolated protein which is a human .alpha..sub.1c adrenergic receptor, vectors comprising an isolated nucleic acid molecule encoding a human .alpha..sub.1a adrenergic receptor, vectors comprising an isolated nucleic acid molecule encoding a human .alpha..sub.1b adrenergic receptor, and vectors comprising an isolated nucleic acid molecule encoding a human .alpha..sub.1c adrenergic receptor, mammalian cells comprising such vectors, antibodies directed to the human .alpha..sub.1a adrenergic receptor, antibodies directed to the human .alpha..sub.

Abstract: This invention provides an isolated nucleic acid molecule encoding a human Y2 receptor, an isolated protein which is a human Y2 receptor, vectors comprising an isolated nucleic acid molecule encoding a human Y2 receptors, mammalian cells comprising such vectors, antibodies directed to the human Y2 receptor, nucleic acid probes useful for detecting nucleic acid encoding human Y2 receptors, antisense oligonucleotides complementary to any sequences of a nucleic acid molecule which encodes a human Y2 receptor, pharmaceutical compounds related to human Y2 receptors, and nonhuman transgenic animals which express DNA a normal or a mutant human Y2 receptor. This invention further provides methods for determining ligand binding, detecting expression, drug screening, and treatment involving the human Y2 receptor.

Abstract: This invention provides an isolated nucleic acid molecule encoding a human Y4 receptor, an isolated protein which is a human Y4 receptor, vectors comprising an isolated nucleic acid molecule encoding a human Y4 receptors, mammalian cells comprising such vectors, antibodies directed to the human Y4 receptor, nucleic acid probes useful for detecting nucleic acid encoding human Y4 receptors, antisense oligonucleotides complementary to any sequences of a nucleic acid molecule which encodes a human Y4 receptor, pharmaceutical compounds related to human Y4 receptors, and nonhuman transgenic animals which express DNA a normal or a mutant human Y4 receptor. This invention further provides methods for determining ligand binding, detecting expression, drug screening, and treatment involving the human Y4 receptor.

Abstract: This invention provides an isolated nucleic acid molecule encoding a human 5-HT.sub.1E receptor, an isolated protein which is a human 5-HT.sub.1E receptor, vectors comprising an isolated nucleic acid molecule encoding a human 5-HT.sub.1E receptors, mammalian cells comprising such vectors, antibodies directed to the human 5-HT.sub.1E receptor, nucleic acid probes useful for detecting nucleic acid encoding human 5-H.sub.1E receptors, antisense oligonucleotides complementary to any sequences of a nucleic acid molecule which encodes a human 5-HT.sub.1E receptor, pharmaceutical compounds related to human 5-HT.sub.1E receptors, and nonhuman transgenic animals which express DNA a normal or a mutant human 5-HT.sub.1E receptor. This invention further provides methods for determining ligand binding, detecting expression, drug screening, and treatment involving the human 5-HT.sub.1E receptor.

Abstract: This invention provides an isolated nucleic acid molecule encoding a mammalian 5-HT.sub.4A receptor and an isolated nucleic acid molecule encoding a human 5-HT.sub.4A receptor, an isolated protein which is a mammalian 5-HT.sub.4A receptor, an isolated protein which is a human 5-HT.sub.4A receptor, vectors comprising an isolated nucleic acid molecule encoding a mammalian 5-HT.sub.4A receptor, vectors comprising an isolated nucleic acid molecule encoding a human 5-HT.sub.4A receptor, mammalian cells comprising such vectors, antibodies directed to the 5-HT.sub.4A receptor, nucleic acid probes useful for detecting nucleic acid encoding a mammalian or human 5-HT.sub.4A receptor, antisense oligonucleotides complementary to any sequences of a nucleic acid molecule which encodes a mammalian or human 5-HT.sub.4A receptor, pharmaceutical compounds related to the human 5-HT.sub.4A receptor, and nonhuman transgenic animals which express DNA encoding a normal or a mutant mammalian or human 5-HT.sub.4A receptor.

Abstract: This invention provides an isolated nucleic acid molecule encoding a human 5-HT.sub.1F receptor, an isolated protein which is a human 5-HT.sub.1F receptor, vectors comprising an isolated nucleic acid molecule encoding a human 5-HT.sub.1F receptors, mammalian cells comprising such vectors, antibodies directed to the human 5-HT.sub.1F receptor, nucleic acid probes useful for detecting nucleic acid encoding human 5-HT.sub.1F receptors, antisense oligonucleotides complementary to any sequences of a nucleic acid molecule which encodes a human 5-HT.sub.1F receptor, pharmaceutical compounds related to human 5-HT.sub.1F receptors, and nonhuman transgenic animals which express DNA a normal or a mutant human 5-HT.sub.1F receptor. This invention further provides methods for determining ligand binding, detecting expression, drug screening, and treatment involving the human 5-HT.sub.1F receptor.

Abstract: This invention provides isolated nucleic acid molecules encoding human 5-HT.sub.1D receptors, isolated proteins which are human 5-HT.sub.1D receptors, vectors comprising isolated nucleic acid molecules encoding human 5-HT.sub.1D receptors, mammalian cells comprising such vectors, antibodies directed to the human 5-HT.sub.1D receptors, nucleic acid probes useful for detecting nucleic acid encoding human 5-HT.sub.1D receptors, antisense oligonucleotides complementary to any sequences of a nucleic acid molecule which encodes a human 5-HT.sub.1D receptor, pharmaceutical compounds related to human 5-HT.sub.1D receptors, and nonhuman transgenic animals which express DNA a normal or a mutant human 5-HT.sub.1D receptor. This invention further provides methods for determining ligand binding, detecting expression, drug screening, and treatment involving the human 5-HT.sub.1D receptor.

Abstract: The present invention provides an isolated nucleic acid molecule encoding an .alpha..sub.2B -adrenergic receptor, and an isolated protein which is a human .alpha..sub.2B -adrenergic receptor.The invention also provides vectors comprising DNA molecules encoding a human .alpha..sub.2B -adrenergic receptor, and vectors adapted for expression of the .alpha..sub.2B -adrenergic receptor in bacterial, yeast, or mammalian cells.In addition, the invention provides a DNA probe useful for detecting nucleic acid encoding the .alpha..sub.2B -adrenergic receptor, a method for determining whether a ligand which is not known to be capable of binding to the .alpha..sub.2B -adrenergic receptor can bind to the .alpha..sub.2B -adrenergic receptor, a method for detecting the presence of .alpha..sub.2B -adrenergic receptor on the surface of a cell, and a method of screening drugs to identify drugs which specifically interact with, and bind to, the .alpha..sub.2B -adrenergic receptor.